Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by FrancoQcon Jun 21, 2017 10:47pm
424 Views
Post# 26390673

Thomvest : exercise it's Pre-Emptive Right at 1.70 $

Thomvest : exercise it's Pre-Emptive Right at 1.70 $On SEDAR:

CONCURRENT PRIVATE PLACEMENT

Under the Third Loan Agreement dated April 27, 2017, entered into between Prometic, certain of its affiliates, and Structured Alpha, an affiliate of Thomvest Seed Capital Inc., Prometic granted a pre-emptive right to Structured Alpha to participate in any future public offering or private placement of Prometic’s common shares or securities convertible or exchangeable into common shares of Prometic (the “Pre-Emptive Right”). Structured Alpha has delivered a notice dated June 16, 2017 to Prometic with respect to the exercise of the Pre-Emptive Right in connection with the Offering. As a result of this notice and concurrently with the Offering, the Corporation is completing a private placement of 5,045,369 Common Shares with Structured Alpha at a price of $1.70 per Common Share, representing a value of $8,577,127 plus an additional 759,774 Common Shares at a price of $1.70 per Common Share representing a value of $1,291,615, if the Over-Allotment Option is exercised in full (the “Concurrent Private Placement”). The Concurrent Private Placement is expected to close simultaneously with the Offering. However, the Offering is not conditional on the closing of the Concurrent Private Placement. The Common Shares issuable under the Concurrent Private Placement do not form part of the Offering and will be subject to a statutory hold period. The Underwriters are not acting in connection with, and no fee or commission will be paid to the Underwriters in respect of, the Common Shares sold under the Concurrent Private Placement.

En franais:

Structured Alpha a livr un avis Prometic dat du 16 juin 2017 l’informant qu’elle exerait le droit de premption relativement au placement. la suite de cet avis et paralllement au placement, la Socit procde un placement priv de 5 045 369 actions ordinaires au prix de 1,70 $ l’action ordinaire auprs de Structured Alpha reprsentant une valeur de 8 577 127 $, ainsi que de 759 774 actions ordinaires supplmentaires au prix de 1,70 $ l’action ordinaire reprsentant une valeur de 1 291 615 $, si l’option de surallocation est intgralement exerce (le « placement priv concomitant »).

Good to know that they will exercise their "Pre-Emptive right" at 1.70 $

GLTA longs,

FrancoQc

Bullboard Posts